Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Electron s Revenue Climbs 24 Percent in Q2, Though Profit Slides 34 Percent

NEW YORK, July 27 (GenomeWeb News) - Thermo Electron today reported increased revenues but reduced earnings for the second quarter of 2005.


Total revenues for the quarter were $653.6 million, up 24% over revenues during the same period last year, which were $525.3 million. Fifteen percent of this revenue growth was due to acquisitions. The company's life and laboratory sciences unit recorded $487 million in revenues, up a third over $370 million during the year-ago period.


Research and development costs were $39.4 million, up from $32.6 million during the same quarter last year.


Thermo's net income fell 44 percent to $60.2 million, or $.37 per share, from $91.1 million, or $.54 per share, during the year-ago period. Last year's second quarter included a gain of $.24 per share from discontinued operations.


As of July 2, Thermo had $159.7 million in cash and cash equivalents, and $11.1 million in short-term available-for-sale investments.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.